Pyxis Oncology Gets Fast Track Designation For PYX-201 In Head And Neck Cancer
26/2 14:35
(RTTNews) - Pyxis Oncology, Inc. (PYXS) Wednesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PYX-201, the company's drug candidate for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcino...